On this page
  1. What semaglutide is
  2. Ozempic vs. Wegovy vs. Rybelsus
  3. How much weight people lose
  4. Beyond weight: the heart data
  5. Common questions
Quick answer

Semaglutide is a GLP-1 medication sold as Ozempic and Rybelsus for type 2 diabetes and, at a higher dose, as Wegovy for weight management. In its main weight-loss trial, adults lost about 14.9% of their body weight over 68 weeks, against 2.4% on placebo.

Semaglutide is the active ingredient behind three brand names you've probably already heard. It's the same molecule each time, but the dose, the form, and the FDA approval change from one to the next. That's where most of the confusion starts.

Below is what the drug does, the real difference between Ozempic, Wegovy, and Rybelsus, and what the trials measured when people took it to lose weight.

What semaglutide is

Semaglutide belongs to a class called GLP-1 receptor agonists. It copies glucagon-like peptide-1, a hormone your gut releases after you eat. According to StatPearls (NCBI, 2024), these drugs slow how fast the stomach empties, prompt the pancreas to release insulin when blood sugar rises, and act on appetite centers in the brain. The practical effect is that you feel full sooner, stay full longer, and think about food less.

Most forms are a once-weekly injection you give yourself with a small pen. One version, Rybelsus, is a daily tablet. A clinician walks you through how to use either form and what to expect in the first few weeks.

Ozempic vs. Wegovy vs. Rybelsus

All three are semaglutide. What separates them is the dose and what the FDA approved each one to treat:

  • Ozempic is a weekly injection approved for type 2 diabetes. Doctors prescribe it off-label for weight loss, which is part of why its name became shorthand for the whole category.
  • Wegovy is the higher-dose semaglutide approved for chronic weight management. It now comes two ways: the original once-weekly injection (2.4 mg) and, since December 2025, a once-daily 25 mg tablet.
  • Rybelsus is an oral semaglutide tablet approved for type 2 diabetes, not weight loss. You take it on an empty stomach with a small sip of water, then nothing else by mouth for 30 minutes, or it won't absorb properly (MedlinePlus, 2026).

The oral Wegovy tablet is the new piece here. The FDA approved it in December 2025 as the first GLP-1 pill cleared for weight loss, after the OASIS 4 trial, in which people who stayed on it lost about 16.6% of their body weight, on par with the injection (FDA, 2025). If pills versus injections is your question, the oral GLP-1 guide goes deeper.

Wondering if semaglutide fits you? A U.S.-licensed Vyta.co clinician reviews your history and, when it's appropriate, sends treatment to your pharmacy. Compounded from $159/mo, or brand-name Wegovy.
See your options

How much weight people lose

The number most people want comes from the STEP 1 trial, published in the New England Journal of Medicine in 2021 (Wilding et al.). Nearly 2,000 adults with obesity, none with diabetes, took weekly semaglutide at 2.4 mg or placebo for 68 weeks alongside lifestyle changes. Average weight loss was 14.9% of body weight on semaglutide versus 2.4% on placebo. About 86% of people on the drug lost at least 5% of their weight, and roughly half lost 15% or more.

Two caveats keep those numbers honest. Results vary widely from person to person, and they depend on staying on the medication. When people stop, appetite returns and most of the weight tends to come back, which is why clinicians treat semaglutide as ongoing therapy rather than a short course. Tirzepatide, the other major option, posted higher average loss in its own trials; the head-to-head comparison lays out how they differ.

Beyond weight: the heart data

Semaglutide also did something older weight-loss drugs were never shown to do. In the SELECT trial (New England Journal of Medicine, 2023), more than 17,000 adults with established cardiovascular disease and overweight or obesity, but without diabetes, took weekly semaglutide or placebo. The drug cut the risk of major cardiovascular events (cardiovascular death, heart attack, or stroke) by about 20%. On the strength of that result, the FDA added a heart-risk-reduction use for injectable Wegovy in 2024.

For the right patient, the cardiovascular benefit reframes the whole conversation. We're no longer only talking about a number on the scale; we're talking about lowering the risk of a heart attack.

— John Venzor, DO

Semaglutide isn't right for everyone, and a few groups should not take it at all.

When to seek care

Semaglutide is not for you if you or a close relative has had medullary thyroid carcinoma or the genetic syndrome MEN 2, or if you've had pancreatitis. It is not used in pregnancy or while breastfeeding.

Stop and seek care for severe, persistent abdominal pain (sometimes spreading to the back), which can signal pancreatitis or a gallbladder problem. Our side-effects guide covers the warning signs in full.

Common questions

Yes, semaglutide is the active ingredient in Ozempic. It's also the ingredient in Wegovy and Rybelsus. The brands differ by dose and by what the FDA approved each one to treat, but the molecule itself is identical.
Most people notice a smaller appetite within the first few weeks, but real weight loss builds over months. The dose is raised slowly to limit nausea, and the STEP 1 trial measured its 14.9% average loss at 68 weeks, so the full effect takes close to a year.
Most people regain much of the weight after stopping. Appetite returns once the medication leaves your system, which is why clinicians treat semaglutide as ongoing therapy rather than a short course. Staying on it, paired with diet and activity, is what holds the results.
You shouldn't take semaglutide if you or a close relative has had medullary thyroid carcinoma or MEN 2, or if you've had pancreatitis. It also isn't used during pregnancy or while breastfeeding. A clinician reviews your history before prescribing to rule these out.